Within a very short period of time, there has been a tremendous advance in development of cellular immunotherapies in multiple myeloma (MM). As we have observed during our event last year, a number of groups have presented their data on CAR T-cell therapy in MM. Although the studies are currently small in size, they are accruing patients very quickly, both in the United States and globally.

These developments have highlighted the need for a focused discussion about the state-of-the-art in immune and cellular therapies. With this in mind, the International Myeloma Society (IMS) is organizing the 2nd Immune Effector Cell Therapy in Multiple Myeloma Workshop. This two-day meeting will review CAR-T clinical data and promising preclinical leads, gain consensus on issues in management of toxicity, and discuss ongoing and future clinical trials. This year we are also including a session on T cell-engaging bispecific antibody-based approaches.
Friday, April 3, 2020

8:00-8:15 am  Introduction and Welcome Remarks
   Adam Cohen, MD; Hermann Einsele, MD, FRCP; and Nikhil Munshi, MD

8:15-8:30 am  How will CAR T and bispecifics fit in MM treatment paradigm?
   Kenneth Anderson, MD

SESSION 1: UPDATE ON BCMA CAR T CLINICAL DATA
(Session Chairs: Nikhil Munshi, MD and Paula Rodriguez-Otero, MD)

8:30-8:45 am  Legend LCAR-B38M update
   TBC

8:45-9:00 am  CARTITUDE-1 phase 1 update
   Deepu Madduri, MD

9:00-9:15 am  bb2121/KARMMA ph1 + 2 update
   Noopur Raje, MD

9:15-9:30 am  Juno JCAR125/EVOLVE update
   Sham Mailankody, MBBS

9:30-9:45 am  CT053/Carsgen
   Hong Ma, MD

9:45-10:00 am  Discussion

10-10:30 am  Break

SESSION 2: NEXT GENERATION BCMA CAR PRODUCTS IN THE CLINIC
(Session Chairs: William Bensinger, MD and Kwee Yong, MBBS, PhD)

10:30-10:45 am  bb21217
   Jesus Berdeja, MD

10:45-11:00 am  BCMA CAR + gamma secretase inhibition
   Damian Green, MD

11:00-11:15 am  Poseida transposon CAR
   Caitlin Costello, MD

11:15-11:30 am  Autolus APRIL based CAR
   Martin Pule, MD

11:30-11:45 am  NCI heavy chain based BCMA CAR
   TBC

11:45-12:00 pm  Discussion

12:00-1:00 pm  Lunch

1:00-1:30 pm  Keynote Address: Making CAR T cells work better
   Michel Sadelain, MD, PhD
### SESSION 3: CAR T CELL CORRELATIVE ANALYSES: UNDERSTANDING RESPONSE AND RESISTANCE
(Session Chairs: Madhav V. Dhodapkar, MBBS and Paola Neri, MD, PhD)

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30-1:45 pm</td>
<td>Correlates of response and resistance to CAR T cells: Lessons from CD19 experience</td>
<td>TBC</td>
</tr>
<tr>
<td>1:45-2:00 pm</td>
<td>Single cell immune profiling after CAR T therapy in MM</td>
<td>Samir Parekh, MBBS</td>
</tr>
<tr>
<td>2:00-2:15 pm</td>
<td><strong>bb2121 correlatives</strong></td>
<td>Ethan G. Thompson, PhD</td>
</tr>
<tr>
<td>2:15-2:30 pm</td>
<td><strong>CARTITUDE-1 correlatives</strong></td>
<td>Enrique Zudaire, PhD</td>
</tr>
<tr>
<td>2:30-2:45 pm</td>
<td><strong>Penn CART-BCMA correlatives</strong></td>
<td>Adam Cohen, MD</td>
</tr>
<tr>
<td>2:45-3:00 pm</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>3:00-3:30 pm</td>
<td>Break</td>
<td></td>
</tr>
</tbody>
</table>

### SESSION 4: BEYOND BCMA: ALTERNATIVE CAR TARGETS
(Session Chairs: Amrita Krishnan, MD and Mohamad Mohty, MD, PhD)

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:30-3:45 pm</td>
<td>Rationale for targeting CD19</td>
<td>Alfred Garfall, MD</td>
</tr>
<tr>
<td>3:45-4:00 pm</td>
<td><strong>Combined BCMA and CD19 CAR T cells</strong></td>
<td>TBC</td>
</tr>
<tr>
<td>4:00-4:15 pm</td>
<td><strong>CD38 CAR T cells</strong></td>
<td>Tuna Mutis, MD, PhD</td>
</tr>
<tr>
<td>4:15-4:30 pm</td>
<td><strong>GPRC5D CAR T cells</strong></td>
<td>Eric Smith, MD, PhD</td>
</tr>
<tr>
<td>4:30-4:45 pm</td>
<td><strong>SLAMF7 CAR T cells</strong></td>
<td>Krina K. Patel, MD, MSc</td>
</tr>
<tr>
<td>4:45-5:00 pm</td>
<td><strong>SLAMF7 CAR T cells</strong></td>
<td>Michael Hudecek, MD</td>
</tr>
<tr>
<td>5:00-5:15 pm</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

### Saturday, April 4, 2020

### SESSION 5: NOVEL CELL THERAPY APPROACHES FOR MM
(Session Chairs: Sagar Lonial, MD, FACP and Marc S. Raab, MD, PhD)

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00-8:15 am</td>
<td>CRISPR/Cas9-edited NYESO-1 specific T cells</td>
<td>Edward Stadtmauer, MD</td>
</tr>
<tr>
<td>8:15-8:30 am</td>
<td><strong>ALLO-715 and other off-the-shelf CARs for MM</strong></td>
<td>TBC</td>
</tr>
</tbody>
</table>
8:30-8:45 am  MIL-based CAR T cell therapy  
Ivan Borrello, MD

8:45-9:00 am  Vaccines to augment cell therapy  
David Avigan, MD

9:00-9:15 am  NK based CAR T cells  
TBC

9:15-9:30 am  BAT CARs  
Carl Novina, MD, PhD

9:30-9:45 am  Discussion

9:45-10:00 am  Break

SESSION 6: BISPECIFIC ANTIBODIES/T CELL ENGAGERS FOR MM  
(Session Chairs: Suzanne Trudel, MD and Hearn Cho, MD)

10:00-10:15 am  AMG420  
Hermann Einsele, MD, FRCP

10:15-10:30 am  CC-93269  
Luciano J. Costa, MD, PhD

10:30-10:45 am  REGN5458  
Dennis Cooper, MD

10:45-11:00 am  PF-06863135  
Alexander Lesokhin, MD

11:00-11:15 am  Non-BCMA bispecific antibodies in development for MM  
TBC

11:15-11:30 am  Mitigating CRS from bispecific antibodies  
Teemu Junttila, PhD

11:30-11:45 am  Discussion

SESSION 7: TOXICITIES OF IMMUNE CELL THERAPY  
(Session Chairs: Sundar Jagannath, MD and David S. Siegel, MD, PhD)

11:45-12:00 pm  Pathophysiology and predictors of CRS  
Yi Lin, MD, PhD

12:00-12:15 pm  Management of CRS in 2020: Beyond toci/steroids?  
Nina Shah, MD

12:15-12:30 pm  Understanding and managing CAR T neurotoxicity  
Bianca D. Santomasso, MD, PhD

12:30-12:45 pm  Discussion

12:45 pm  Close and Lunch
THANK YOU TO OUR SPONSORS

This program is supported by a grant from Celgene Corporation.

International Myeloma Society
www.myelomasociety.org